10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.875.1999



# Collagen I Rabbit pAb

Collagen I Rabbit pAb Catalog # AP94077

#### **Product Information**

**Application** WB, IHC-P, IHC-F, IF

**Primary Accession** P02452

Reactivity Human, Mouse, Rat, Rabbit

Host Rabbit Clonality Polyclonal Calculated MW 138911 **Physical State** Liquid

**Immunogen** KLH conjugated synthetic peptide derived from human Collagen I

1051-1150/1464 **Epitope Specificity** 

Isotype IgG

affinity purified by Protein A **Purity** 

**Buffer** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

SUBCELLULAR LOCATION Secreted, extracellular space, extracellular matrix.

Belongs to the fibrillar collagen family. Contains 1 fibrillar collagen NC1 **SIMILARITY** 

domain. Contains 1 VWFC domain.

**SUBUNIT** Trimers of one alpha 2(I) and two alpha 1(I) chains. Interacts with MRC2.

Interacts with TRAM2. Subcellular Location: Secreted, extracellular space,

extracellular matrix.

Post-translational Proline residues at the third position of the tripeptide repeating unit (G-X-P) modifications

are hydroxylated in some or all of the chains. Proline residues at the second position of the tripeptide repeating unit (G-P-X) are hydroxylated in some of the chains. O-linked glycan consists of a Glc-Gal disaccharide bound to the

oxygen atom of a post-translationally added hydroxyl group.

Defects in COL1A1 are the cause of Caffey disease (CAFFD) [MIM:114000]; also **DISEASE** 

> known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic

> fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age. Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type 1 (EDS1) [MIM:130000]; also known as

Ehlers-Danlos syndrome gravis. EDS is a connective tissue disorder

characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS1 is the severe form of classic Ehlers-Danlos syndrome. Defects in COL1A1 are the cause of Ehlers-Danlos syndrome type 7A (EDS7A) [MIM:130060]; also known as autosomal dominant Ehlers-Danlos syndrome type VII. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint

hyperlaxity. EDS7A is marked by bilateral congenital hip dislocation,

hyperlaxity of the joints, and recurrent partial dislocations. Defects in COL1A1 are a cause of osteogenesis imperfecta type 1 (OI1) [MIM:166200]. A dominantly inherited connective tissue disorder characterized by bone fragility and blue sclerae. Osteogenesis imperfecta type 1 is non-deforming

1 of 4

with normal height or mild short stature, and no dentinogenesis imperfecta. Defects in COL1A1 are a cause of osteogenesis imperfecta type 2 (OI2) [MIM:166210]; also known as osteogenesis imperfecta congenita. A connective tissue disorder characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency. Defects in COL1A1 are a cause of osteogenesis imperfecta type 3 (OI3) [MIM:259420]. A connective tissue disorder characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta. Defects in COL1A1 are a cause of osteogenesis imperfecta type 4 (OI4) [MIM:166220]; also known as osteogenesis imperfecta with normal sclerae. A connective tissue disorder characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta. Genetic variations in COL1A1 are a cause of susceptibility to osteoporosis (OSTEOP) [MIM:166710]; also known as involutional or senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture. Note=A chromosomal aberration involving COL1A1 is found in dermatofibrosarcoma protuberans. Translocation t(17;22)(q22;q13) with PDGF.

**Important Note** 

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

**Background Descriptions** 

Collagens are highly conserved throughout evolution and are characterised by an uninterrupted "Glycine X Y" triplet repeat that is a necessary part of the triple helical structure. Type I collagen (95 kDa) is found in bone, cornea, skin and tendon. Mutations in the encoding gene are associated with osteogenesis imperfecta, Ehlers Danlos syndrome, and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for Platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor.

### **Additional Information**

Gene ID 1277

Other Names Collagen alpha-1(I) chain, Alpha-1 type I collagen, COL1A1

**Target/Specificity** Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are

mineralized with calcium hydroxyapatite.

**Dilution** WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500

Format 0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce

Storage Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When

reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody

is stable for at least two weeks at 2-4 °C.

#### **Protein Information**

Name COL1A1

**Function** Type I collagen is a member of group I collagen (fibrillar forming collagen).

**Cellular Location** Secreted, extracellular space, extracellular matrix

{ECO:0000255 | PROSITE-ProRule:PRU00793}


**Tissue Location** Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are

mineralized with calcium hydroxyapatite


## **Background**

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.


## **Images**



Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Collagen I) Polyclonal Antibody, Unconjugated (AP94077) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.




Sample: Lane 1: Placenta (Mouse) Lysate at 40 ug Lane 2: U-2OS (Human) Cell Lysate at 30 ug Primary: Anti-Collagen I (AP94077) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 130 kD Observed band size: 130 kD



Sample: Ovary (Mouse) Lysate at 40 ug NIH/3T3(Mouse) Cell Lysate at 40 ug Liver (Rat)Lysate at 40 ug 293T(huamn) Cell Lysate at 40 ug A431(huamn) Cell Lysate at 40 ug RAW264.7(Mouse) Cell Lysate at 40 ug Primary: Anti-Collagen I (AP94077) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 130 kD Observed band size: 110 kD

Tissue/cell: human lung carcinoma; 4%
Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min; Incubation:
Anti-Collagen I Polyclonal Antibody,
Unconjugated(AP94077) 1:200, overnight at 4°C, followed



by conjugation to the secondary antibody (SP-0023) and  $\ensuremath{\mathsf{DAB}}(\ensuremath{\mathsf{C}}\xspace\text{-}0010)$  staining

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.